Clinical trials
Medulloblastoma clinical trials
Below are recruiting medulloblastoma clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07664176RecruitingPhase 1
Focused ultrasound plus nivolumab for children with brain tumors
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
Washington D.C., District of ColumbiaAges 3–25 - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT06779487Recruiting
Predicting memory changes from brain radiation
This study looks for biomarkers in your blood that might predict how radiation treatment affects brain function. The goal is to understand and possibly reduce cognitive side effects.
Mumbai, MaharashtraAges 5–39 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT06804655RecruitingPhase 2
Personalized drug testing for stubborn brain tumors
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
Basel, Basel-LandschaftAges 18 years+ - NCT06624371RecruitingPhase 1
Atovaquone with radiation for children with brain tumors
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
Atlanta, GeorgiaAges 2–25 - NCT06193759RecruitingPhase 1
Immune cell therapy for malignant pediatric brain tumors
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Washington D.C., District of ColumbiaAges 1–30 - NCT06161519RecruitingPhase 1/Phase 2
PLX038 for brain tumors with MYC or MYCN changes
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Bethesda, MarylandAges 18–120 - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT05298995RecruitingPhase 1
GD2 CAR T-cell treatment for pediatric brain tumors
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
Roma, ItalyAges 6 months–30 years - NCT05230758RecruitingPhase 3
Metformin trial for brain tumor survivors’ brain and behavior
This Phase 3 study tests whether metformin can improve brain function, behavior, and thinking in children and teens who were treated for certain brain tumors. You may be able to join if you meet age, time-since-treatment, language, and health/lab safety requirements.
New Lambton Heights, New South WalesAges 7–21 - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Birmingham, AlabamaAges 3–22
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for medulloblastoma?
- Yes. Clin2 currently lists 39 recruiting medulloblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a medulloblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a medulloblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.